GlassScriptPhysician profile
Karen Hasty
NPI 1053378596
$3,783.16
in general payments reported to CMS, 2019-2025
29 companies · $447 in 2025
The $447 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $375 · 2021: $896 · 2022: $471 · 2023: $566 · 2024: $599 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.43 |
| Education | $165.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.21 | 2019-2024 | |
| Astellas Pharma US INC | $443.55 | 2019-2025 | Veozah |
| Acessa Health INC. | $356.33 | 2021 | |
| Mayne Pharma Commercial LLC | $303.81 | 2023-2025 | |
| Pfizer INC. | $163.00 | 2019-2025 | |
| Therapeuticsmd, INC. | $156.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.15 | 2019-2024 | |
| Avion Pharmaceuticals | $125.94 | 2019-2023 | Balcoltra, NP Thyroid 60 |
| Shield Therapeutics INC | $114.28 | 2023-2025 | Accrufer |
| Millicent US INC | $91.86 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Organon LLC | $91.26 | 2023-2024 | Nexplanon |
| Merck Sharp & Dohme LLC | $81.00 | 2019-2024 | Gardasil, Gardasil 9 |
| Novo Nordisk INC | $75.27 | 2022-2024 | Wegovy |
| Agile Therapeutics, INC. | $71.53 | 2022-2024 | Twirla |
| Hologic Sales and Service, LLC | $67.06 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $57.59 | 2019-2022 | |
| Biogen, INC. | $52.00 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $48.13 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $33.58 | 2020-2024 | Paragard T 380a |
| Aspira Women'S Health INC | $28.58 | 2024 | Ova1 |
| Scynexis, INC. | $22.81 | 2022 | |
| Urovant Sciences INC | $22.42 | 2022 | |
| Acella Pharmaceuticals, LLC | $21.11 | 2025 | NP Thyroid 60 |
| Sientra, INC. | $19.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.67 | 2019 | |
| Abbott Laboratories | $16.96 | 2023 | Proclaim |
| Cumberland Pharmaceuticals, INC. | $15.23 | 2025 | Kristalose |
| Currax Pharmaceuticals LLC | $13.10 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Hasty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.